Eric Quéméneur
Chief Tech/Sci/R&D Officer en TRANSGENE .
Perfil
Eric Quéméneur is currently the Director & EVP-Research & Development at ElsaLys Biotech SAS and the Chief Scientific Officer & Executive VP at Transgene SA. Previously, he worked as the Director-Research Programs at Comité de l’énergie Atomique from 1990 to 2014.
Dr. Quéméneur holds a doctorate degree from Université Claude Bernard Lyon 1 and an undergraduate degree from Institut National des Sciences Appliquées de Lyon, which he obtained in 1986.
Cargos activos de Eric Quéméneur
| Empresas | Cargo | Inicio |
|---|---|---|
| TRANSGENE | Chief Tech/Sci/R&D Officer | 01/09/2014 |
| ELSALYS BIOTECH | Chief Tech/Sci/R&D Officer | - |
Antiguos cargos conocidos de Eric Quéméneur.
| Empresas | Cargo | Fin |
|---|---|---|
| Comité de l’énergie Atomique | Corporate Officer/Principal | 01/09/2014 |
Formación de Eric Quéméneur.
| Université Claude Bernard Lyon 1 | Doctorate Degree |
| Institut National des Sciences Appliquées de Lyon | Undergraduate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 1 |
|---|---|
| TRANSGENE | Health Technology |
| Empresas privadas | 2 |
|---|---|
| Comité de l’énergie Atomique | Government |
ElsaLys Biotech SAS
 ElsaLys Biotech SAS Pharmaceuticals: MajorHealth Technology ElsaLys Biotech SAS provides therapeutic monoclonal antibody player services. It involves in cellular events at the core of the pathological process: immune response, angiogenesis, survival, proliferation, adhesion and migration. The company also designs and develops a new generation of antibodies that target tumors and their immune microenvironment. ElsaLys Biotech was founded by Christine Guillen, Thierry Menguy, Vanessa Duong, and Martine Brandt in 2013 and is headquartered in Lyon, France. | Health Technology |
- Bolsa de valores
- Insiders
- Eric Quéméneur
